Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Tanta University
40 participants
Jul 10, 2025
OBSERVATIONAL
Conditions
Summary
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Eligibility
Inclusion Criteria3
- Prematurity.
- Gestational age between 28 and 36 weeks.
- Suffering from respiratory distress syndrome.
Exclusion Criteria8
- Intrauterine growth restriction (IUGR).
- Hypoxic ischemic encephalopathy.
- Multiple congenital anomalies.
- Chromosomal abnormalities.
- Preterm less than 28 weeks.
- Neonates with a maternal history of chorioamnionitis (early sepsis).
- Infant of diabetic mother.
- Prelabor rupture of membranes (PROM)> 2 hours.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07154134